66th ASH Annual Meeting: 802. Chemical Biology and Experimental Therapeutics: Poster I

Symposia: Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Poster

Research, Viral, Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Lymphomas, Drug development, Translational Research, Assays, Chemotherapy, Plasma Cell Disorders, T Cell lymphoma, Diseases, Treatment Considerations, Infectious Diseases, Biological therapies, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Myeloid Malignancies, Emerging technologies, Technology and Procedures, Molecular testing

Halls G-H (San Diego Convention Center)

2203

High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias

Mithun Sarangdhar, Ph.D.¹^*, Eric O'Brien, B.Sc.¹^*, Brett VanCauwenbergh, B.Sc.¹^*, Mitali Basu, M.Sc.¹^*, Jonah Snyder¹^*, Grace Leuenberger¹^* and John Peter Perentesis, MD²

¹CBDI-Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
²Cincinnati Children's Hospital, Cincinnati, OH

2204

Functional Analysis of EBV-Derived microRNAs in Systemic Chronic Active EBV Disease Using Novel Antisense Oligonucleotides

Miwako Nishio, PhD¹^*, Mayumi Yoshimori, PhD^2,3^*, Kotaro Yoshioka, MD, PhD⁴^*, Yuri Maekawa²^*, Rintaro Hara, PhD⁴^*, Takanori Yokota, MD, PhD⁴^*, Ryusuke Nabeshima, PhD⁵^* and Ayako Arai, MD, PhD^2,6,7

¹Department of Hematology and Biophysical Systems Analysis, Institute of Science Tokyo, Tokyo, Japan
²Department of Hematology and Biophysical Systems Analysis, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
³Center of Blood Transfusion and Cell Therapy, Tokyo Medical and Dental University Hospital (TMDU), Tokyo, Japan
⁴Department of Neurology and Neurological Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
⁵Bioresource Management, Drug Discovery Biologics, Ono Pharmaceutical Co., Ltd, Tokyo, Japan
⁶Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki-Shi, Japan
⁷Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

2205

Characterization of the Biochemical Activity of Ktx-1001, a Selective Small Molecule NSD2 Inhibitor, in Surface Plasmon Resonance (SPR)

Chad A. Lewis, PhD¹^*, Charles Schmidt, PhD²^*, Lisa Beebe, PhD³^* and Terry Connolly, PhD¹^*

¹K36 Therapeutics, Cambridge, MA
²Reaction Biology, Malvern, PA
³BB Preclinical Consulting, Acton, MA

2206

The Endocannabinoid N-Arachidonoyl Dopamine Induces Leukemia Cell Pyroptosis to Overcome the Venetoclax Resistance

Min Wu, MD, PhD¹, Lingyun Tang, PhD²^*, Bo Jiao, PhD³^*, Ping Liu, MD, PhD³^*, Junmin Li, MD, PhD³^* and Ruibao Ren, MD, PhD³

¹Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, AL, China
²State Key Laboratory of Medical Genomics, Research Center for Experimental Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
³Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

2207

Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Mansi Arora, PhD¹^*, Richard Centore, PhD¹^*, Mark Charles, PhD²^*, Yiwen Chen, PhD¹^*, Matthew Watson, PhD²^*, Magdalena Czekalska, PhD²^*, Marius Rebmann, PhD²^*, Mahmoud Ghandi, PhD¹^*, Jerome Cattin, PhD²^*, Nagakumar Bharatham, PhD²^*, Prathima Radhakrishnan, PhD¹^*, Alexander Howarth, PhD²^*, William E Arter, PhD²^*, Seema Qamar, PhD²^*, Laura Andraghetti²^*, Kadi Saar, PhD²^*, Andrew Seeber, PhD¹^*, Michael G. Kharas, PhD³, Martin Kulander²^*, Tuomas Knowles, PhD^2,4^* and Shilpi Arora, PhD¹^*

¹Transition Bio, Inc, Watertown, MA
²Transition Bio, Ltd, Cambridge, United Kingdom
³Memorial Sloan Kettering Cancer Center, New York, NY
⁴University of Cambridge, Cambridge, United Kingdom

2208

Harnessing Ferroptosis and Photothermal Effects: A New Paradigm in Aggressive Lymphoma Therapy

Mengyao Wang, MD^1,2,3^*, Qian Hu, PhD^2,3,4^* and Ting Niu, MD, PhD^3,5,6

¹Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
²State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
³National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China
⁴Department of Hematology, West China Hospital, Sichuan University, Chengdu, AL, China
⁵Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
⁶Department of Hematology, West China Hospital of Sichuan University, Chengdu, China

2209

Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer

Hongwon Lee¹^*, Byungsan Choi, PhD²^*, Saem Hong, MS²^*, Yunseo Lee, BS²^*, Janghee Woo, MD, PhD³ and Tae-Young Yoon, PhD²^*

¹PROTEINA Co., Ltd., Seoul, South Korea
²PROTEINA Co., Ltd., Seoul, Korea, Republic of (South)
³Winship Cancer Institute of Emory University, Atlanta, GA

2210

Targeting Intracellular Mutant NPM1 in Acute Myeloid Leukemia with a Novel Peptide-MHC-Specific T-Cell Bispecific Antibody

Yunda Hong^1,2,3^*, Dabing Chen^3,4,5^*, Jingjing Xu^3,4,5^*, Yanxin Chen, MD, PhD¹^*, Yangtao Wu^6,7^*, Yang Shi^6,7^*, Tianying Zhang^6,7^*, Quan Yuan^6,7^*, Ningshao Xia^6,7^*, Ting Yang^3,4,5^* and Jianda Hu, PhD^1,2,3

¹Fujian Medical University Union Hospital, Fuzhou, China
²The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
³Institute of Precision Medicine, Fujian Medical University, Fuzhou, China
⁴Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
⁵Department of Hematology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China
⁶State Key Laboratory of Vaccines for Infectious Diseases，Xiang An Biomedicine Laboratory，Department of Laboratory Medicine, School of Public Health，Xiamen University, Xiamen, China
⁷National Institute of Diagnostics and Vaccine Development in Infectious Diseases，State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics，National Innovation Platform for Industry-Education Intergration in Vaccine Research，Xiamen University, Xiamen, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

802.P1.24 802. Chemical Biology and Experimental Therapeutics: Poster I